Subtype
Meningeal Neoplasm
CI-CAN-00001210Explore in graph →
Non-malignant111 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001210Explore in graph →
Clinical trials
275 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04729348 | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06809517 | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis | recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06971406 |
| High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) |
| not yet recruiting |
| Phase 2 |
| 100 |
| Qiming WangOTHER_GOV |
| 0 |
| May 14, 2025 |
| clinicaltrials |
| NCT05289908 | Intrathecal Pemetrexed for Leptomeningeal Metastasis | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04997317 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide(PROMENADE) | recruiting | Phase 1 / Phase 2 | 18 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06901817 | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases | recruiting | Phase 2 | 97 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06861218 | Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases | not yet recruiting | Phase 2 | 42 | Zhejiang Cancer HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03016091 | A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma | terminated | Phase 2 | 18 | Rabin Medical CenterOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06710249 | Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema(AFBTEdema) | recruiting | Phase 2 | 20 | Peter SiesjöOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06684795 | FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery | unknown | Phase 2 | 40 | Rigshospitalet, DenmarkOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT01117844 | Proton Radiation For Meningiomas and Hemangiopericytomas | completed | Phase 1 / Phase 2 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06441045 | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI | not yet recruiting | Phase 2 | 112 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 4, 2024 | clinicaltrials |
| NCT02333565 | Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas(CEVOREM) | completed | Phase 2 | 20 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03071874 | Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas | active not recruiting | Phase 2 | 28 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT02831257 | AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | completed | Phase 2 | 18 | Massachusetts General HospitalOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT05385185 | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer | unknown | Phase 2 | 20 | Hebei Medical UniversityOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT00972335 | Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma | terminated | Phase 2 | 18 | SCRI Development Innovations, LLCOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01125046 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | completed | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04425681 | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer(OWBLM) | unknown | Phase 2 | 20 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03936426 | Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™ | completed | Phase 1 / Phase 2 | 5 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Apr 20, 2020 | clinicaltrials |
| NCT03507244 | Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT04148898 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis(OWONBNSCLCLM) | unknown | Phase 2 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03082144 | Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors | completed | Phase 2 | 53 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT00859040 | Monthly SOM230C for Recurrent or Progressive Meningioma | completed | Phase 2 | 34 | Patrick Y. Wen, MDOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT00003483 | Antineoplaston Therapy in Treating Patients With Meningioma | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00045734 | Imatinib Mesylate in Treating Patients With Recurrent Meningioma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 15, 2017 | clinicaltrials |
| NCT00706810 | Combination of Hydroxyurea and Verapamil for Refractory Meningiomas | completed | Phase 2 | 8 | University of UtahOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00003590 | S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma | completed | Phase 2 | 29 | SWOG Cancer Research NetworkNETWORK | 1 | May 20, 2016 | clinicaltrials |
| NCT00589784 | Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | completed | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00003292 | S9624 Ifosfamide in Treating Patients With Meningeal Tumors | terminated | Phase 2 | 7 | SWOG Cancer Research NetworkNETWORK | 4 | Nov 8, 2013 | clinicaltrials |
| NCT01818713 | Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases | unknown | Phase 2 | 6 | The Netherlands Cancer InstituteOTHER | 1 | Oct 29, 2013 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT00005812 | Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma | terminated | Phase 2 | 12 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 14, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jul 25, 2025source: clinicaltrials